Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma

Cancer molecular heterogeneity might explain the variable response of EGFR mutant lung adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the mutational status of 22 cancer genes by next-generation sequencing (NGS) in poor, intermediate or good responders to first-line gefitinib. Clin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Bria, Emilio, Pilotto, Sara, Amato, Eliana, Fassan, Matteo, Novello, Silvia, Peretti, Umberto, Vavalà, Tiziana, Kinspergher, Stefania, Righi, Luisella, Santo, Antonio, Brunelli, Matteo, Corbo, Vincenzo, Giglioli, Eliana, Sperduti, Isabella, Milella, Michele, Chilosi, Marco, Scarpa, Aldo, Tortora, Giampaolo
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4494974/
https://ncbi.nlm.nih.gov/pubmed/25904052
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares